Supplementary Table 5.
Clinical trials | Number of patients (R/C) | Pooled effect size in mmHg (95% CI) | I2 (%) | Phet | Pz |
---|---|---|---|---|---|
All trials pooled | 558/404 | 0.14 (−1.72, 2.00) | 58 | 0.01 | 0.88 |
Excluded trial | |||||
DENERHTN | 510/351 | −0.32 (−2.21, 1.56) | 52 | 0.04 | 0.74 |
DENERVHTA | 547/391 | −0.36 (−2.03, 1.32) | 47 | 0.07 | 0.68 |
OSLO | 549/394 | −0.17 (−2.07, 1.74) | 59 | 0.02 | 0.86 |
Prague-15 | 506/350 | 0.36 (−1.77, 2.49) | 63 | 0.009 | 0.74 |
ReSET | 523/371 | 0.06 (−2.02, 2.15) | 63 | 0.009 | 0.95 |
SYMPLICITY HTN-2 | 538/379 | 0.48 (−1.36, 2.31) | 57 | 0.02 | 0.61 |
SYMPLICITY HTN-3 | 229/242 | 0.39 (−1.89, 2.67) | 61 | 0.01 | 0.74 |
SYMPLICITY HTN-Japan | 536/385 | 0.56 (−1.35, 2.47) | 57 | 0.02 | 0.56 |
SYMPLICITY HTN-Flex | 526/369 | 0.31 (−1.90, 2.51) | 63 | 0.008 | 0.79 |
DBP: Diastolic blood pressure; CI: Confidence interval; C: Control group; Phet: Significance for the heterogeneity test; Pz: Significance for the pooled effect size; R: Renal denervation group.